B. Metzler seel. Sohn & Co’s United Therapeutics UTHR Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$595K	Hold	1,099	–	–	0.01%	638
2026 Q1	$652K	Buy	1,099 +180	+20%	+$89.6K	0.01%	601
2025 Q4	$448K	Hold	919	–	–	﹤0.01%	654
2025 Q3	$385K	Hold	919	–	–	﹤0.01%	674
2025 Q2	$264K	Hold	919	–	–	﹤0.01%	708
2025 Q1	$283K	Sell	919 -41	-4%	-$14.1K	﹤0.01%	699
2024 Q4	$339K	Hold	960	–	–	﹤0.01%	690
2024 Q3	$344K	Hold	960	–	–	﹤0.01%	693
2024 Q2	$306K	Buy	960 +52	+6%	+$13.8K	﹤0.01%	700
2024 Q1	$209K	Buy	+908	New	+$205K	﹤0.01%	743
2023 Q4	–	Sell	-908	Closed	-$205K	–	767
2023 Q3	$205K	Hold	908	–	–	﹤0.01%	704
2023 Q2	$200K	Buy	+908	New	+$201K	﹤0.01%	722

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

B. Metzler seel. Sohn & Co's UTHR Position: Q2 2026 in Review

B. Metzler seel. Sohn & Co held its United Therapeutics (UTHR) position steady in Q2 2026 at 1,099 shares worth $595K. The position accounts for 0.01% of the portfolio, ranked #638.

B. Metzler seel. Sohn & Co first reported a position in UTHR in Q2 2023 and has held it in 12 quarters since. The position peaked at $652K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

B. Metzler seel. Sohn & Co held 1,099 shares of United Therapeutics worth $595K as of Q2 2026.
B. Metzler seel. Sohn & Co left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up 0.01% of B. Metzler seel. Sohn & Co's portfolio in Q2 2026, its #638 holding.
B. Metzler seel. Sohn & Co first reported a position in United Therapeutics in Q2 2023 and has held it in 12 quarters since.
B. Metzler seel. Sohn & Co's United Therapeutics position peaked at $652K in Q1 2026.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2026, filed 11 Aug 2026.